Clinical Trials

UVA Health System frequently opens new clinical trials, offering your patients the latest investigational treatments.

For a complete list of active trials and study coordinator contact information, visit

New Trials Available at UVA

COVID-19 (IRB-HSR #200114)

Efficacy and Safety of High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma for Hospitalized Patients with Infection due to COVID-19 to Decrease Complications: A Phase II Trial (NCT04374565)

Primary Investigator: Jeffrey Sturek

Clinical Research Coordinator: Allison Raymond

Ischemia (IRB-HSR #190044)

Women’s Ischemia Trial to Reduce Events in Non-Obstructive CAD (WARRIOR) (NCT03417388)

Primary Investigator: Angela Taylor

Clinical Research Coordinator: Nicole Sprouse

Gastrointestinal Oncology (IRB-HSR #200056)

Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA) (NCT04068103)

Primary Investigator: Matthew Reilley

Clinical Research Coordinator: Chance Wright

Thoracic Oncology (IRB-HSR #200081)

ETCTN10216: A Phase I/II Study of AZD9291 and CB-839 HCl in Patients with EGFR Mutant Non-Small Cell Lung Cancer (NCT03831932)

Primary Investigator: Richard Hall

Clinical Research Coordinator: Gracie Hockenberry

Cardiac Care (IRB-HSR #21631)

Impact of Baseline Gut Microbiome and Behavioral Interventions on Cardiac Outcomes in Patients Presenting to Cardiovascular Clinic

Primary Investigator: Nishaki Mehta

Clinical Research Coordinator: Katerina Morgaenko

Non-Obstructive CAD in Women (IRB-HSR #190044)

Women’s Ischemia Trial to Reduce Events in Non-Obstructive CAD — WARRIOR (NCT03417388)

Primary Investigator: Angela Taylor

Clinical Research Coordinator: Nicole Sprouse

Acute Myelogenous Leukemia (IRB-HSR #190074)

Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second or Third Salvage (NCT03926624)

Primary Investigator: Michael Keng

Clinical Research Coordinator: Cory Caldwell

Gynecologic Oncology (IRB-HSR #190076)

A Phase 2, Randomized, Open-label, 3-arm Study of Relacorilant in Combination with Nab-Paclitaxel for Patients with Recurrent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT03776812)


Primary Investigator: Linda Duska

Clinical Research Coordinator: Anne Gabel

Asthma (IRB-HSR #19157)

Clinical Response to Rhinovirus Challenge in Human Asthmatics (NCT02910401)


Primary Investigator: Larry Borish

Clinical Research Coordinator: Deborah Murphy

Asthma (IRB-HSR #19512)

Screening Protocol of Asthmatic, Allergic Rhinitic, and Control Participants for Experimental Rhinovirus Challenges (NCT02910401)


Primary Investigator: Larry Borish

Clinical Research Coordinator: Deborah Murphy

Gynecologic Oncology (IRB-HSR #200023)

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum (NCT04095364)


Primary Investigator: Susan Modesitt

Clinical Research Coordinator: Rachel Lacy

Gynecologic Oncology (IRB-HSR #21685)

Atezolizumab in Combination with Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery for Patients with Newly-Diagnosed Advanced-Stage Epithelial Ovarian Cancer (NCT03394885)


Primary Investigator: Kari Ring

Clinical Research Coordinator: Rachel Lacy

Genitourinary Oncology (IRB-HSR #21987)

A Prospective Comparative Study of Outcomes With Proton and Photon Radiation In Prostate Cancer (NCT03561220)


Primary Investigator: Timothy Showalter

Clinical Research Coordinator: Amy Smith

Amyotrophic Lateral Sclerosis (IRB-HSR #21602)

Open-label, Non-Randomised Extension Trial to Assess the Long-Term Safety and Efficacy of 1200 mg/day Arimoclomol Citrate 400 mg Three Times a Day (t.i.d.) in Subjects with Amyotrophic Lateral Sclerosis (ALS) who have Completed the ORARIALS-01 Trial (NCT03836716)

Primary Investigator: Matthew Elliott

Clinical Research Coordinator: Mary Wagoner

Genitourinary Oncology (IRB-HSR #21771)

A Multicenter Phase IIb Trial to Evaluate the Efficacy and Tolerability of ModraDoc006/r in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC), Suitable for Treatment With a Taxane (NCT04028388)

Primary Investigator: Robert Dreicer

Hematologic Malignancies (IRB-HSR #21781)

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (NCT03657160)

Primary Investigator: Leonid Volodin

Clinical Research Coordinator: Megan Healy

Hematologic Malignancies (IRB-HSR #21795)

A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

Primary Investigator: Laahn Foster

Clinial Research Coordinator: Sharon Johnson

Myasthenia Gravis (IRB-HSR #21943)

A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis having Generalized Muscle Weakness (NCT03770403)

Primary Investigator: Sarah Jones

Clinical Research Coordinator: Mary Wagoner

Hematologic Malignancies (IRB-HSR #21188)

Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia (NCT03258931)

Primary Investigator: Michael Keng

Genitourinary Oncology (IRB-HSR #21680)

A Phase II trial of sEphB4-HSA in combination with ANti PD1 Antibody Pembrolizumab (MK-3475) for metastatic urothelial cancer refractory to platinum. (NCT02717156)

Primary Investigator: Michael Devitt

Clinical Research Coordinator: Jennifer Drake